Patient Preferences for Multiple Myeloma Treatments : A Multinational Qualitative Study

Show simple item record

dc.contributor.author Janssens, Rosanne
dc.contributor.author Lang, Tamika
dc.contributor.author Vallejo, Ana
dc.contributor.author Galinsky, Jayne
dc.contributor.author Plate, Ananda
dc.contributor.author Morgan, Kate
dc.contributor.author Cabezudo, Elena
dc.contributor.author Silvennoinen, Raija
dc.contributor.author Coriu, Daniel
dc.contributor.author Badelita, Sorina
dc.contributor.author Irimia, Ruxandra
dc.contributor.author Anttonen, Minna
dc.contributor.author Manninen, Riikka-Leena
dc.contributor.author Schoefs, Elise
dc.contributor.author Vandebroek, Martina
dc.contributor.author Vanhellemont, Anneleen
dc.contributor.author Delforge, Michel
dc.contributor.author Stevens, Hilde
dc.contributor.author Simoens, Steven
dc.contributor.author Huys, Isabelle
dc.date.accessioned 2021-09-21T09:36:02Z
dc.date.available 2021-09-21T09:36:02Z
dc.date.issued 2021-07-06
dc.identifier.citation Janssens , R , Lang , T , Vallejo , A , Galinsky , J , Plate , A , Morgan , K , Cabezudo , E , Silvennoinen , R , Coriu , D , Badelita , S , Irimia , R , Anttonen , M , Manninen , R-L , Schoefs , E , Vandebroek , M , Vanhellemont , A , Delforge , M , Stevens , H , Simoens , S & Huys , I 2021 , ' Patient Preferences for Multiple Myeloma Treatments : A Multinational Qualitative Study ' , Frontiers in Medicine , vol. 8 , 686165 . https://doi.org/10.3389/fmed.2021.686165
dc.identifier.other PURE: 168640674
dc.identifier.other PURE UUID: 3afd1d65-d5a4-4735-aea6-f34f55d3ce2e
dc.identifier.other WOS: 000674466800001
dc.identifier.uri http://hdl.handle.net/10138/334482
dc.description.abstract Background: Investigational and marketed drugs for the treatment of multiple myeloma (MM) are associated with a range of characteristics and uncertainties regarding long term side-effects and efficacy. This raises questions about what matters most to patients living with this disease. This study aimed to understand which characteristics MM patients find most important, and hence should be included as attributes and levels in a subsequent quantitative preference survey among MM patients. Methods: This qualitative study involved: (i) a scoping literature review, (ii) discussions with MM patients (n = 24) in Belgium, Finland, Romania, and Spain using Nominal Group Technique, (iii) a qualitative thematic analysis including multi-stakeholder discussions. Results: MM patients voiced significant expectations and hopes that treatments would extend their lives and reduce their cancer signs and symptoms. Participants however raised concerns about life-threatening side-effects that could cause permanent organ damage. Bone fractures and debilitating neuropathic effects (such as chronic tingling sensations) were highlighted as major issues reducing patients' independence and mobility. Patients discussed the negative impact of the following symptoms and side-effects on their daily activities: thinking problems, increased susceptibility to infections, reduced energy, pain, emotional problems, and vision problems. MM patients were concerned with uncertainties regarding the durability of positive treatment outcomes, and the cause, severity, and duration of their symptoms and side-effects. Patients feared short-term positive treatment responses complicated by permanent, severe side-effects and symptoms. Conclusions: This study gained an in-depth understanding of the treatment and disease-related characteristics and types of attribute levels (severity, duration) that are most important to MM patients. Results from this study argue in favor of MM drug development and individual treatment decision-making that focuses not only on extending patients' lives but also on addressing those symptoms and side-effects that significantly impact MM patients' quality of life. This study underscores a need for transparent communication toward MM patients about MM treatment outcomes and uncertainties regarding their long-term efficacy and safety. Finally, this study may help drug developers and decision-makers understand which treatment outcomes and uncertainties are most important to MM patients and therefore should be incorporated in MM drug development, evaluation, and clinical practice. en
dc.format.extent 17
dc.language.iso eng
dc.relation.ispartof Frontiers in Medicine
dc.rights cc_by
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject multiple myeloma
dc.subject patient preferences
dc.subject nominal group technique
dc.subject qualitative research
dc.subject attributes
dc.subject drug development
dc.subject regulatory benefit-risk assessment
dc.subject health technology assessment
dc.subject DISCRETE-CHOICE EXPERIMENTS
dc.subject DATA SATURATION
dc.subject NOMINAL GROUP
dc.subject 3122 Cancers
dc.title Patient Preferences for Multiple Myeloma Treatments : A Multinational Qualitative Study en
dc.type Article
dc.contributor.organization Department of Oncology
dc.contributor.organization University of Helsinki
dc.contributor.organization Hematologian yksikkö
dc.contributor.organization HUS Comprehensive Cancer Center
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.3389/fmed.2021.686165
dc.relation.issn 2296-858X
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
fmed_08_686165.pdf 662.3Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record